Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - A European multicentre study

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 8, 1998, Pages 789-795

  Dekkers, C P M ^a   Beker, J A ^b   Thjodleifsson, B ^c   Gabryelewicz, A ^d   Bell, N E ^e   Humphries, T J ^e  

^a Ignatius Hospital   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; ASTHENIA; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FLU LIKE SYNDROME; GASTRIN BLOOD LEVEL; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; STOMACH ULCER; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PAIN; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0031871921     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00373.x     Document Type: Article

References (15)

1. Sachs G, Prinz CK, Hersey SJ. Acid-Related Disorders. Mystery to Mechanism: Mechanism to Management. Palm Beach, FL: Sushu Publishing Inc. 1995: 72-85.
2. Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. A low dose of a new proton pump inhibitor LY307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology 1996; 110: A16(Abstract).
3. Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
4. + activity and nocturnal acid secretion in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
5. Humphries TJ, Cloud ML, Enas N, Bassion S, McNamara M, & the US Rabeprazole Gastric Ulcer Study Group. Rabeprazole (E3810, LY307640) achieves high rates of healing in active gastric ulcer. Gastroenterology 1996; 110: A138(Abstract).
6. Cloud ML, Enas N, Humphries TJ, Bassion S and the Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases. Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastro-oesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
7. Humphries TJ, Nardi RV, Lazar JD, Spanyers SA. Drug-drug interaction evaluation of rabeprazole sodium. A clean/expected slate? Gut 1996; 39(Suppl. 3): A47(Abstract).
8. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RN. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effort to healing rates. Dig Dis Sci 1988; 33: 619-24.
9. Bate CM, Wilkinson SP, Bradby GUH, Bateson MC, Hislop WS, Willoughby CP, et al. Randomized, double-blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut 1989; 30: 1323-8.
10. Walan A, Bader J-P, Classen M, Lamers CBHW, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastriculcer. N Engl J Med 1989; 320: 69-75.
11. Schepp W, Rehner M, Witzel L. A review of treatment of duodenal and gastric ulcers - pantoprazole vs. omeprazole. Aliment Pharmacol Ther 1994; 8(Suppl.): 53-7.
12. Witzel L, Gutz H, Huttemann W, Schepp W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995; 9: 19-24.
13. Hahn EG, Erlangen Bosseckert H, Jena Dammann HG. Tolerability and safety protile of pantoprazole based on 100.134 patients, results of German Post Marketing Surveillance (PMS) Program. Gastroenterology 1997; 112: A138(Abstract).
14. Avner DL, Movva R, Nelson KJ, McFarland M, Berry W, Erfling W. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. Am J Gastroenterol 1995; 90: 1289-94.
15. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 36: 22438-46.